---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009416"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:34:32.886187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Panbela Q4 net loss $6.5M; ASPIRE trial >50% enrolled; cash $2.6M

## Summary
- Net loss of $6.5M ($65.90/share) in Q4 2023 vs. $4.7M loss in Q4 2022.
- Cash $2.6M at Dec 31, 2023; raised ~$9M in Jan 2024 registered offering.
- ASPIRE Phase III trial for metastatic pancreatic cancer exceeds 50% enrollment; full enrollment (~600 patients) expected Q1 2025.
- Research and development expense $6.1M in Q4, up from $3.5M year-over-year.
- Divestiture of pediatric neuroblastoma program to US WorldMeds for up to $9.5M.

## SEC filing metadata
- accession: 0001437749-24-009416
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/0001437749-24-009416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/pbla20240326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009416
- JSON: https://secwatch.observer/filing/0001437749-24-009416.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009416.txt

## Key facts
- Earnings Releases
  Panbela Therapeutics, Inc. reported the quarter and full year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, EPS $65.90 per diluted share.
  - Period: the quarter and full year ended December 31, 2023
  - Net income: Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share
  - EPS: $65.90 per diluted share
  - Result: reported results
  source text: Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, compared to a net loss of $4.7 million, or $344.61 per diluted share, in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/0001437749-24-009416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.